AssetMark Inc’s Ligand Pharmaceuticals LGND Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.31M | Buy |
6,570
+379
| +6% | +$75K | ﹤0.01% | 979 |
|
|
2025
Q4 | $1.17M | Buy |
6,191
+6,068
| +4,933% | +$1.17M | ﹤0.01% | 982 |
|
|
2025
Q3 | $21.8K | Buy |
123
+75
| +156% | +$11.2K | ﹤0.01% | 1888 |
|
|
2025
Q2 | $5.46K | Buy |
48
+22
| +85% | +$2.35K | ﹤0.01% | 2111 |
|
|
2025
Q1 | $2.73K | Sell |
26
-58
| -69% | -$6.56K | ﹤0.01% | 2113 |
|
|
2024
Q4 | $9K | Buy |
84
+54
| +180% | +$6.1K | ﹤0.01% | 1811 |
|
|
2024
Q3 | $3K | Buy |
30
+4
| +15% | +$403 | ﹤0.01% | 1805 |
|
|
2024
Q2 | $2.19K | Hold |
26
| – | – | ﹤0.01% | 1733 |
|
|
2024
Q1 | $1.9K | Buy |
+26
| New | +$1.92K | ﹤0.01% | 1591 |
|
|
2022
Q1 | – | Sell |
-32
| Closed | -$3K | – | 1666 |
|
|
2021
Q4 | $3K | Buy |
+32
| New | +$2.96K | ﹤0.01% | 1323 |
|
|
2020
Q4 | – | Sell |
-10
| Closed | -$1K | – | 1456 |
|
|
2020
Q3 | $1K | Hold |
10
| – | – | ﹤0.01% | 1246 |
|
|
2020
Q2 | $1K | Sell |
10
-3,717
| -100% | -$236K | ﹤0.01% | 1184 |
|
|
2020
Q1 | $169K | Sell |
3,727
-314
| -8% | -$17.8K | ﹤0.01% | 513 |
|
|
2019
Q4 | $263K | Buy |
4,041
+3,533
| +695% | +$236K | ﹤0.01% | 502 |
|
|
2019
Q3 | $32K | Buy |
508
+498
| +4,980% | +$31.3K | ﹤0.01% | 809 |
|
|
2019
Q2 | $1K | Hold |
10
| – | – | ﹤0.01% | 1248 |
|
|
2019
Q1 | $1K | Hold |
10
| – | – | ﹤0.01% | 1258 |
|
|
2018
Q4 | $1K | Hold |
10
| – | – | ﹤0.01% | 1329 |
|
|
2018
Q3 | $2K | Hold |
10
| – | – | ﹤0.01% | 1274 |
|
|
2018
Q2 | $1K | Hold |
10
| – | – | ﹤0.01% | 1348 |
|
|
2018
Q1 | $1K | Sell |
10
-1,683
| -99% | -$166K | ﹤0.01% | 1344 |
|
|
2017
Q4 | $145K | Buy |
1,693
+1,305
| +336% | +$113K | ﹤0.01% | 512 |
|
|
2017
Q3 | $33K | Sell |
388
-22
| -5% | -$1.74K | ﹤0.01% | 809 |
|
|
2017
Q2 | $31K | Sell |
410
-2
| -0.5% | -$140 | ﹤0.01% | 796 |
|
|
2017
Q1 | $27K | Sell |
412
-48
| -10% | -$3.16K | ﹤0.01% | 792 |
|
|
2016
Q4 | $29K | Buy |
460
+5
| +1% | +$316 | ﹤0.01% | 772 |
|
|
2016
Q3 | $29K | Sell |
455
-52
| -10% | -$3.82K | ﹤0.01% | 767 |
|
|
2016
Q2 | $38K | Buy |
507
+286
| +129% | +$21.2K | ﹤0.01% | 668 |
|
|
2016
Q1 | $15K | Buy |
221
+191
| +637% | +$11.6K | ﹤0.01% | 802 |
|
|
2015
Q4 | $2K | Buy |
+30
| New | +$1.85K | ﹤0.01% | 1104 |
|
Other funds holding LGND
VPM
VCM
NAMI
CC
AssetMark Inc's LGND Position: Q1 2026 in Review
AssetMark Inc increased its Ligand Pharmaceuticals (LGND) stake by 6.1% in Q1 2026, buying an estimated $75K and bringing the position to 6,570 shares worth $1.31M. The position accounts for ﹤0.01% of the portfolio, ranked #979.
AssetMark Inc first reported a position in LGND in Q4 2015 and has held it in 30 quarters since. 357 funds tracked by Wall St. Rank hold LGND as of Q1 2026.
- AssetMark Inc held 6,570 shares of Ligand Pharmaceuticals worth $1.31M as of Q1 2026.
- AssetMark Inc bought 379 Ligand Pharmaceuticals shares in Q1 2026, an estimated $75K.
- Ligand Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q1 2026, its #979 holding.
- AssetMark Inc first reported a position in Ligand Pharmaceuticals in Q4 2015 and has held it in 30 quarters since.
- 357 funds tracked by Wall St. Rank held Ligand Pharmaceuticals as of Q1 2026.
Based on AssetMark Inc's 13F filing for Q1 2026, filed 6 May 2026.